Mission Therapeutics

Executive Summary

Mission Therapeutics is a clinical-stage biotechnology company pioneering first-in-class small molecule inhibitors of deubiquitylating enzymes (DUBs) to treat diseases with high unmet need. Headquartered in Cambridge, UK, the company's lead program targets Parkinson's disease by enhancing mitochondrial quality control through selective DUB inhibition. Mission's platform also extends to fibrosis, heart and kidney diseases, and rare mitochondrial disorders, leveraging a unique approach to modulate protein homeostasis. With a robust preclinical pipeline and early clinical data suggesting target engagement, Mission is positioned to address key mechanisms in neurodegeneration and fibrotic disease. The company's strategy centers on developing disease-modifying therapies rather than symptomatic treatments, offering potential for significant clinical impact. Recent financing and academic collaborations underscore growing investor confidence in its DUB platform. Anticipated upcoming milestones include clinical data readouts and pipeline expansion into new indications, which could catalyze partnering interest and valuation inflection.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 data readout for lead DUB inhibitor in Parkinson's disease60% success
• Q3 2026Preclinical proof-of-concept data for fibrosis program50% success
• Q2 2026Series C financing or strategic partnership70% success